Search
forLearn
5 / 801 resultslearn Piroctone Olamine
learn retinoic acid
learn retinol
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Research
5 / 640 results
research Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in the Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design
The combination of cyclosporine and PUVA might help treat severe alopecia areata.
research Phototherapy in Childhood
Phototherapy is effective and well-tolerated for treating childhood psoriasis and pityriasis lichenoides chronica.
research Ultrastructure study of hair damage after ultraviolet irradiation
UV treatment can damage hair, so protection is advised.
research Topical and intralesional therapies for alopecia areata
Many treatments for alopecia areata have inconsistent results; for under 10s, use minoxidil with a corticosteroid, and for over 10s, add ILC and consider diphenylcyclopropenone for widespread cases.
research Dermatological drugs, topical agents, and cosmetics
The document concluded that various dermatological treatments have different effectiveness and side effects, with some causing irritation, allergic reactions, or systemic effects.
Community Join
5 / 1000+ resultscommunity Verteporfin Update #1: Overview of Verteporfin Procedure Day | Feller & Bloxham Medical
The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
community Verteporfin scar/regrowth Update Day 84
Hair loss discussion mentions treatments Minoxidil, Finasteride, and RU58841. Verteporfin shows promise for scar/regrowth after 84 days.
community Medications that cause extra hair growth
The post discusses the side effects of various drugs causing excess hair growth, questioning why only minoxidil is used in the hair loss industry. The conversation includes users sharing their experiences and concerns about potential side effects of these drugs, with some preferring baldness over potential health risks.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Verteporfin update - donor hair regeneration human trial
A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.